The Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer – BCAN New Discoveries Young Investigator Award – Eugene J. Pietzak

Eugene Pietzak, MD, Assistant Attending Surgeon of Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York City received one of the five 2021 Bladder Cancer Advocacy Network (BCAN) New Discoveries Young Investigator Awards for his work in “Defining the Clinical Impact and Molecular Drivers of ‘Secondary’ Muscle-Invasive Bladder Cancer.” There are relatively well-established…

Read the full article here

Source: UroToday

Categories: General Medicine News, Latest Headlines

Tags: BladderCancer

Tweets with this article

UroToday.com

The clinical impact and molecular drivers of ‘secondary’ muscle-invasive #BladderCancer. @BladderCancerUS new discoveries young investigator award. @eugene_pietzak @sloan_kettering joins @UroDocAsh @MDAndersonNews for a discussion on UroToday > https://t.co/wg6fE11YMm https://t.co/cDgwbgXZAi

Who are the Mentors of the Future Endourologist? An Analysis of Endourological Society Program Directors – Beyond the Abstract

urology, endourology, endourology mentorship, urology mentorship, Endourological Society’s accreditation, Endourological Society-accredited urology fellowship programs, future of urological care and research.

UroToday.com April 24, 2024

Treatment Decision Making in mHSPC: The Medical Oncologist and Patient “What the Patient Needs to Know” About this Disease and Treatment Options? – Brenda Martone

Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies:…

UroToday.com April 24, 2024

Atezolizumab Monotherapy versus Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor130): Final Overall Survival Analysis from a Randomised, Controlled, Phase 3 Study – Beyond the Abstract

bladder cancer, Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma, Atezolizumab, IMvigor130 trial, metastatic urothelial carcinoma (mUC), PD-L1 expression, CheckMate 901…

UroToday.com April 24, 2024

Clinical Outcomes in Response to Perioperative Chemotherapy in Bladder Cancer – Expert Commentary

bladder cancer (BC), neoadjuvant chemotherapy after radical cystectomy (RC), gemcitabine/cisplatin, MVAC/dose-dense MVAC, gemcitabine/carboplatin, circulating tumor DNA.

UroToday.com April 24, 2024

Comparative Analysis of Robot-Assisted and Open Approach for PSMA-Radioguided Surgery in Recurrent Prostate Cancer – Beyond the Abstract

prostate cancer, Prostate specific membrane antigen (PSMA), positron emission tomography (PET), PSMA PET, PSMA-radioguided surgery (PSMA-RGS), PSMA-Radioguided Surgery in Recurrent Prostate Cancer, Robot-Assisted and Open…

UroToday.com April 24, 2024

Related Articles